Anand Parikh was named President and Chief Executive Officer of Faeth Therapeutics, Inc., effective June 13, 2026. As of November 6, 2026, Faeth Therapeutics, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 16, 2026 to October 27, 2026, naming 6 appointments (Form 8-K, June 15, 2026).
Faeth Therapeutics, Inc. named a new Director on Sep 17. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Faeth Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Adam Schayowitz · Role: Director · 8-K, 2026-10-27
- · In / out: In · Person: Karen Vousden · Role: Director · 8-K, 2026-09-17
- · In / out: In · Person: Anand Parikh · Role: President and Chief Executive Officer · Effective: 2026-06-13 · 8-K, 2026-06-15
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-10
- · In / out: In · Person: Stephen M. Hahn · Role: Director · 8-K, 2026-04-16
Faeth Therapeutics, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-16 to 2026-10-27. They name 5 people. Every row below is cited to the filing it comes from, and this page adds each new change as Faeth Therapeutics, Inc. files it.
Also on the record for Faeth Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G, by VK Services, LLC | 10.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Caligan Partners LP | 2.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by StemPoint Capital LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Trails Edge Capital Partners, LP | 2% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13G, by S2G Investments, LLC | 9.99% of the class | 5%+ stakes | Source |
| June 23, 2026 | Stake report, Schedule 13G, by Suvretta Capital Management, LLC | 7.8% of the class | 5%+ stakes | Source |
| June 3, 2026 | Stake report, Schedule 13G/A, by ICS Opportunities II LLC | 3.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Caligan Partners LP | 9.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Millennium Management LLC | 9.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by StemPoint Capital LP | 9.9% of the class | 5%+ stakes | Source |
| March 4, 2026 | Form D, private offering | $348.91M sold | Form D page | Source |
| February 25, 2026 | Stake report, Schedule 13G, by Trails Edge Capital Partners, LP | 9.9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Faeth Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Faeth Therapeutics, Inc. and the records around it.
Faeth Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Mar 2026
- Who owns it
Companies that share a holder
- S2G Investments, LLC also filed stake reports on 1 other company: Once Upon a Farm, PBC (Feb 2026)
- Khosla Ventures VI, LP also filed stake reports on 2 other companies: BioAge Labs, Inc. (May 2026), Serve Robotics Inc. (Sep 2025)
- StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026), Xilio Therapeutics, Inc. (Aug 2026)
Watch Faeth Therapeutics, Inc.
Get an email when Faeth Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Faeth Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Faeth Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Faeth Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-27 | In | Director | 8-K, 2026-10-27 | ||
| 2026-09-17 | In | Director | 8-K, 2026-09-17 | ||
| 2026-09-17 | In | 8-K, 2026-09-17 | |||
| 2026-06-15 | In | President and Chief Executive Officer | 2026-06-13 | 8-K, 2026-06-15 | |
| 2026-06-15 | In | Chief Financial Officer | 2026-06-13 | 8-K, 2026-06-15 | |
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 | ||
| 2026-04-16 | In | Director | 8-K, 2026-04-16 |
Who leads Faeth Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Adam Schayowitz, appointed (filed 2026-10-27).
- Chief Financial Officer: Brian Stephenson, appointed, effective 2026-06-13 (filed 2026-06-15).
- President and Chief Executive Officer: Anand Parikh, appointed, effective 2026-06-13 (filed 2026-06-15).
New leaders reset buying decisions — get the Full Report on Faeth Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Faeth Therapeutics, Inc., with the record behind each one.
Find candidates like Director at Faeth Therapeutics, Inc.Every change, in the filing's words
Appointed: Adam Schayowitz, Director
On October 23, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company") increased the size of the Board from six to seven directors and appointed Adam Schayowitz to serve as a Class III director, effective immediately.
- Dr. Schayowitz will hold office until the Company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal.
- Adam Schayowitz, Ph.D. (age 46) has served as Executive Vice President and Head of Research and Development of Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company, since April 2026.
- He served as its Acting Chief Development Officer from October 2025 to March 2026.
- Dr. Schayowitz also served as an Operating Partner at EcoR1 Capital, LLC, a biotech-focused investment advisory firm, from September 2024 to March 2026.
- Before EcoR1, he held roles of increasing responsibility at Pfizer Oncology from January 2018 to September 2024, including development leadership roles in breast cancer, prostate cancer, colorectal cancer and melanoma, most recently as Vice President, Head of Product Development Teams.
- Before Pfizer, he led the development of Zejula (niraparib) at Tesaro, Inc. and was a member of the Medical Affairs leadership team at Algeta ASA, where he supported the commercialization of Xofigo (radium-223).
- He previously served on the boards of directors of Scorpion Therapeutics, Inc. and Terremoto Biosciences, Inc. and as a board observer for Aktis Oncology, Inc., and he currently serves on the board of directors of Prostate Cancer Research, a non-profit organization.
Appointed: Karen Vousden, Director
On September 11, 2026, the Board of Directors (the "Board") of Faeth Therapeutics, Inc. (the "Company") increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.
Appointed: Karen Vousden
Dr. Vousden has been elected as a Fellow of the Royal Society, the Royal Society of Edinburgh, the Academy of Medical Sciences, EMBO, the European Academy of Sciences, the American Association of Cancer Research and the American Academy of Arts and Sciences, and as a Foreign Associate of the U.S. National Academy of Sciences.
- Dr. Vousden will hold office until the Company's 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or her earlier death, resignation or removal.
- Dr. Vousden was also appointed to serve as a member of the Compensation Committee of the Board, effective immediately.
- Dr. Vousden (Age 68) is a cancer biologist who has been recognized for her work on the regulation and function of the p53 tumor suppressor protein.
- Dr. Vousden has served as Principal Group Leader of The Francis Crick Institute since February 2017.
- From 2016 to 2022, she served as the Chief Scientist of Cancer Research UK and was director of the Beatson Institute of Cancer Research from 2002 to 2016.
- Dr. Vousden has served on the board of directors of Bristol Myers Squibb Company, a publicly traded biopharmaceutical company, since 2018, where she is a member of the Science and Technology Committee and the Compensation and Management Development Committee.
- Dr. Vousden received her Ph.D. in genetics from Queen Mary College at the University of London.
- The Board believes that Dr. Vousden's extensive experience in cancer biology research, leadership roles at prominent scientific institutions, co-founding of the Company and prior service on a public company board of directors qualify her to serve on our Board.
Appointed: Anand Parikh, President and Chief Executive Officer, effective 2026-06-13
Chief Executive Officer Appointment The Board of Directors (the "Board") of the Company appointed Anand Parikh as President and Chief Executive Officer of the Company, effective as of June 13, 2026 (the "Effective Date").
Appointed: Brian Stephenson, Chief Financial Officer, effective 2026-06-13
Effective as of June 13, 2026, Brian Stephenson was appointed as the Company's Chief Financial Officer and principal financial officer.
- Anand Parikh (Age 40) currently serves as the Company's Chief Operating Officer and member of the Board, positions he has held since February 2026.
- Mr. Parikh previously served as the Chief Executive Officer, Co-Founder and member of the Board of Directors of Faeth Therapeutics, Inc. since its inception in April 2019.
- Prior to co-founding Faeth, Mr. Parikh served in multiple executive roles at Virta Health beginning in May 2015, including General Counsel, Head of Finance and Head of Human Resources.
- Mr. Parikh holds a J.D. from New York University School of Law and a B.A. in Political Science from the University of Michigan.
- In connection with Mr. Parikh's appointment, the Board approved for Mr. Parikh an annual base salary of $680,000 and a target annual bonus of 60% of his base salary.
- Upon a Covered Termination occurring during the Change in Control Period, Mr. Parikh is instead entitled to enhanced cash severance equal to 18 months of base salary paid in a lump sum, a lump-sum bonus payment equal to 1.5x of Mr. Parikh's target annual bonus, Company-paid COBRA premiums for up to 18 months, and full acceleration of all then-outstanding time-based equity awards.
Reported
The 2026 Plan has an initial share reserve equal to (i) 2,671,981 shares of the Company's common stock, par value $0.0001 per share (" common stock ") plus up to (ii) 311,164 shares of common stock subject to outstanding stock awards granted under the Company's 2021 Equity Incentive Plan that, after the date the 2026 Plan becomes effective, are not issued because a stock award expires or otherwise terminates without all of the shares covered by the award having been issued; are not issued because the stock award is settled in cash; are forfeited or repurchased because of the failure to vest; o
- On June 10, 2026, Sensei Biotherapeutics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting").
- At the Annual Meeting, the Company's stockholders approved (i) the Company's 2026 Equity Incentive Plan (the "2026 Plan") and (ii) the Company's 2026 Employee Stock Purchase Plan (the "2026 ESPP").
- The 2026 ESPP has an initial share reserve equal to 267,198 shares of common stock.
- The Board previously approved the 2026 Plan and 2026 ESPP on April 10, 2026, and approved the grant of an option award, in each case, subject to stockholder approval.
- A summary of the principal features of the 2026 Plan and 2026 ESPP are set forth under the headings "Proposal No. 5 - Approval of the 2026 Equity Incentive Plan" and "Proposal No. 6 - Approval of the 2026 ESPP" contained in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 27, 2026 (the "Proxy Statement").
Appointed: Stephen M. Hahn, Director
Upon the effectiveness of their respective appointments, it is expected that: Dr. Hahn will serve as a Class III director and as a member of the Nominating and Corporate Governance Committee of the Board; Ms. Ramasastry will serve as a Class III director and as a member of the Audit Committee and of the Compensation Committee of the Board; and Ms. Vousden will serve as a Class II director and as a member of the Compensation Committee and as Chair of the Nominating and Corporate Governance Committee of the Board.
- For a description of the Conversion Proposal and the Charter Amendment Proposal, please refer to the Company's preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 16, 2026 (the "Preliminary Proxy Statement").
- The decisions of the Resigning Directors to resign were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Conditional Appointments of New Directors In connection with the foregoing, on April 10, 2026, the Board approved the conditional appointments of each of Stephen M. Hahn, Saira Ramasastry, and Karen Vousden (collectively, the "Incoming Directors") to the Board, effective as of the Effective Time.
- The Company intends to enter into its standard form of indemnification agreement with each of the Incoming Directors upon the effectiveness of their respective appointments.
- Upon the effectiveness of such appointment, Mr. Parikh will cease to serve as Chief Operating Officer and will serve as the Company's Chief Executive Officer and principal executive officer.
- It is expected that Mr. Parikh will continue to serve as a member of the Board.
- Also upon the effectiveness of such appointment, Mr. Gerry, the Company's President, General Counsel and a member of the Board, will cease to serve as the Company's President and principal executive officer.
Tools for this story
Each opens in a new tab, filled in for Faeth Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.